Thursday, April 18, 2013 7:25:54 PM
4/18/13
GW Pharmaceuticals, which develops and commercializes cannabinoid-based therapeutics, announced terms for its IPO on Thursday. The stock currently trades on the AIM in London under the symbol GWP. The Wilshire, United Kingdom-based company plans to raise approximately $40 million by offering 3.5 million shares at a price to be determined by its price on the AIM. The last reported price of the shares on the AIM was £0.59 per share, which is the equivalent to $10.79 per ADS based on an assumed exchange rate of £0.6562 to $1.00. At a $10.79 offer price, GW Pharmaceuticals would command a market value of $158 million.
GW Pharmaceuticals, which was founded in 1998 and booked $53 million in sales for the 12 months ended 9/30/2012, plans to list on the NASDAQ under the symbol GWPH. GW Pharmaceuticals initially filed confidentially on 12/14/2012. Lazard Capital Markets and Cowen & Company are the joint bookrunners on the deal.
Keywords/Tickers: GWPH
FEATURED Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM
BNCM COMPLETES MERGER WITH DELEX HEALTHCARE • BNCM • Oct 8, 2024 9:54 AM
CBD Life Sciences, Inc. (CBDL) Reaches Unprecedented Heights With Explosive Growth and Strategic Expansion in 2024 • CBDL • Oct 8, 2024 8:00 AM
Unitronix Corp. to Invest $3 Million in USA Unity Coin Project • UTRX • Oct 7, 2024 7:08 AM